Adjuvant Capital
New York City - Shanghai - Valley California - Palo Alto California | United States
| Investor Type | VC Firm |
| Type of Fund | Venture Capital Fund |
| Industries | BioTech • FinTech (& Financials services) • HealthTech (& Fitness) • Impact • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Life Science • Consumer • Pharmaceutical (& Medicine) • Diagnostics |
| Stages | Seed, Series A, Series B |
| Investing | United States • United Kingdom • Australia • Germany • Switzerland • Netherlands • Denmark • Belgium • Austria |
| Investment Range | $100,000 - $300,000,000 |
| Investment Sweet Spot | $1,500,000 |
| Assets Under Management | $300,000,000 |
What is Adjuvant Capital?
Adjuvant Capital is a venture capital firm with a mission to deploy capital into the most promising life science technologies aimed at addressing high-burden public health challenges.
Operating with an investment sweet spot of $1,500,000 and a fund range of $100,000 to $5,000,000, the firm supports projects through Seed, Series A, and Series B funding stages, with a focus on building a healthier future for all, especially in underserved markets.
Their portfolio targets innovations for infectious diseases such as HIV/AIDS, tuberculosis, malaria, tropical diseases including schistosomiasis and onchocerciasis, as well as pandemic threats like Middle East Respiratory Syndrome (MERS), Lassa fever, and tackling antimicrobial resistance (AMR).
Adjuvant Capital prioritizes maternal and child health, nutrition, and reproductive and sexual health technologies. They are driven by larger global trends such as climate change, women's empowerment, urbanization, and globalization which help guide their investments towards innovations designed for impactful medical advancements.
Their unique expertise and vision are centered on leveraging life science investment to generate both social and financial returns, by fostering novel technologies designed to improve global health, and ensuring accessibility for those in greatest need.
With assets under management worth $300,000,000, they stand dedicated to fostering growth in life sciences sectors traditionally overlooked by investment capital, thereby generating differentiated "double-bottom-line" returns for investors.
Adjuvant Capital distinguishes itself from traditional venture capital firms through its commitment to improving global health, investing in an evolving world, and backing innovations that promise transformative impacts on public health in emerging economies and low-income populations.
What they say:
We are an investment firm dedicated to improving health worldwide.
What we look for: We invest in life sciences and global health initiatives.
Adjuvant Capital's investments on record
What are the investment firms similar to Adjuvant Capital
BT Growth Capital
Allele Capital Partners
AZ-VC
C3 Ventures
Aero X Ventures
Kickstart Fund
Anthropocene Ventures
Asahi Kasei Corporate Venture Capital
Brighton Park Capital
Aliya Capital Partners
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 71-75 Shelton Street, Covent Garden, WC2H 9JQ
- London, U.K.
- contact@angelspartners.com
